Nicholas D. Kindon

1.0k total citations
27 papers, 764 citations indexed

About

Nicholas D. Kindon is a scholar working on Molecular Biology, Organic Chemistry and Physiology. According to data from OpenAlex, Nicholas D. Kindon has authored 27 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Organic Chemistry and 10 papers in Physiology. Recurrent topics in Nicholas D. Kindon's work include Adenosine and Purinergic Signaling (10 papers), Receptor Mechanisms and Signaling (8 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Nicholas D. Kindon is often cited by papers focused on Adenosine and Purinergic Signaling (10 papers), Receptor Mechanisms and Signaling (8 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Nicholas D. Kindon collaborates with scholars based in United Kingdom, Australia and United States. Nicholas D. Kindon's co-authors include Ian Fleming, Anthony H. Ingall, David M. Hodgson, Christopher D. Bray, Wendy Tomlinson, Robert G. Humphries, J. A. Clegg, Barrie Kellam, Michael J. Stocks and John Dixon and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and SHILAP Revista de lepidopterología.

In The Last Decade

Nicholas D. Kindon

27 papers receiving 731 citations

Peers

Countries citing papers authored by Nicholas D. Kindon

Since Specialization

Citations

This map shows the geographic impact of Nicholas D. Kindon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas D. Kindon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas D. Kindon more than expected).

Fields of papers citing papers by Nicholas D. Kindon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas D. Kindon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas D. Kindon. The network helps show where Nicholas D. Kindon may publish in the future.

Co-authorship network of co-authors of Nicholas D. Kindon

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas D. Kindon. A scholar is included among the top collaborators of Nicholas D. Kindon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas D. Kindon. Nicholas D. Kindon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cannabidiol and fluorinated derivative anti-cancer properties against glioblastoma multiforme cell lines, and synergy with imidazotetrazine agents 2024 ·SHILAP Revista de lepidopterología ·(unknown), Nicholas D. Kindon, David J. Scurr, Morgan R. Alexander, Pavel Gershkovich, Tracey D. Bradshaw	1
2	CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans 2024 ·Science Signaling ·Carl W. White, (unknown), Laura E. Kilpatrick, (unknown), (unknown), (unknown), Nicholas D. Kindon, Barrie Kellam, Michael J. Stocks, Kevin D. G. Pfleger, Stephen J. Hill	10
3	Ligand-Directed Labeling of the Adenosine A₁ Receptor in Living Cells 2024 ·Journal of Medicinal Chemistry ·(unknown), Joëlle Goulding, (unknown), Marleen Groenen, Jeanette Woolard, Nicholas D. Kindon, (unknown), (unknown), Stephen J. Briddon, Laura E. Kilpatrick, Peter J. Scammells, Stephen J. Hill, Barrie Kellam	2
4	Small-Molecule Fluorescent Ligands for the CXCR4 Chemokine Receptor 2023 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Joëlle Goulding, Nicholas D. Kindon, Laura E. Kilpatrick, Leigh A. Stoddart, Stephen J. Briddon, Barrie Kellam, Stephen J. Hill, Michael J. Stocks	7
5	Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A₁ Receptor in Living Cells 2021 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Thi Nguyen, Cameron J. Nowell, Nicholas D. Kindon, Mark Soave, Leigh A. Stoddart, Jonathan M. White, Stephen J. Hill, Barrie Kellam, Michelle L. Halls, Lauren T. May, Peter J. Scammells	11
6	Ligand-directed covalent labelling of a GPCR with a fluorescent tag in live cells 2020 ·Communications Biology ·Leigh A. Stoddart, Nicholas D. Kindon, (unknown), (unknown), (unknown), Dmitry B. Veprintsev, Jeanette Woolard, Stephen J. Briddon, Hester Franks, Stephen J. Hill, Barrie Kellam	28
7	Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A_2A Receptor 2019 ·Journal of Medicinal Chemistry ·(unknown), Nicholas D. Kindon, Mark Soave, Leigh A. Stoddart, Laura E. Kilpatrick, Peter J. Scammells, Stephen J. Hill, Barrie Kellam	25
8	Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y₂ Receptor Based on AR-C118925 2018 ·Journal of Medicinal Chemistry ·(unknown), Nicholas D. Kindon, Jacqueline R. Glenn, Leigh A. Stoddart, Richard J. Lewis, Stephen J. Hill, Barrie Kellam, Michael J. Stocks	24
9	Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists 2017 ·ACS Medicinal Chemistry Letters ·Nicholas D. Kindon, Glen K. Andrews, Andrew Baxter, David R. Cheshire, Paul Hemsley, Timothy A. Johnson, Yuzhen Liu, Dermot F. McGinnity, Mark McHale, Antonio Mete, (unknown), Bryan Roberts, John Steele, Barry Teobald, John Unitt, Deborah W. Vaughan, Iain A. S. Walters, Michael J. Stocks	14
10	Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C–C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhibitors 2017 ·Journal of Medicinal Chemistry ·(unknown), Barrie Kellam, (unknown), Stephen J. Hill, Nicholas D. Kindon, Tracey D. Bradshaw, Jin Li, Simon J. F. Macdonald, James E. Rowedder, Leigh A. Stoddart, Michael J. Stocks	8
11	From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor 2017 ·Bioorganic & Medicinal Chemistry Letters ·Nicholas D. Kindon, A. M. Davis, Iain G. Dougall, John Dixon, Timothy A. Johnson, Iain A. S. Walters, (unknown), K. McKechnie, Premji Meghani, Michael J. Stocks	27
12	From libraries to candidate: The discovery of new ultra long-acting dibasic β2-adrenoceptor agonists 2011 ·Bioorganic & Medicinal Chemistry Letters ·Lilian Alcaraz, Andrew Bailey, Elaine Cadogan, Stephen Connolly, (unknown), (unknown), Nicholas D. Kindon, (unknown), Mandy Lawson, (unknown), Ian Dainty, David Nicholls, Stuart W. Paine, Garry Pairaudeau, Michael J. Stocks, (unknown), Alan Young	12
13	The discovery of new spirocyclic muscarinic M3 antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Michael J. Stocks, Lilian Alcaraz, Andrew Bailey, Keith Bowers, David K. Donald, (unknown), (unknown), Nicholas D. Kindon, Garry Pairaudeau, (unknown), Daniel J. Warner	12
14	Synthesis andC-Alkylation of Hindered Aldehyde Enamines 2008 ·The Journal of Organic Chemistry ·David M. Hodgson, Christopher D. Bray, Nicholas D. Kindon, (unknown), Steven J. Coote, Joann M. Um, K. N. Houk	28
15	Hit-to-Lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists 2003 ·Bioorganic & Medicinal Chemistry Letters ·Andrew Baxter, (unknown), (unknown), (unknown), (unknown), Anne Cooper, (unknown), Nicholas D. Kindon, Tom McInally, (unknown), Bryan Roberts, John Unitt	31
16	3 The Medicinal Chemistry of the P2 Receptor Family 2001 ·Progress in medicinal chemistry ·Simon D. Guile, (unknown), Anthony H. Ingall, Nicholas D. Kindon, Premji Meghani, (unknown)	21
17	P2T Purinoceptor Antagonists. A QSAR Study of Some 2-Substituted ATP Analogues 1996 ·Journal of Pharmacy and Pharmacology ·(unknown), (unknown), (unknown), Dermot Cox, A. M. Davis, Darren R. Flower, Nigel P. Gensmantel, Robert G. Humphries, Anthony H. Ingall, Nicholas D. Kindon	5
18	Pharmacological profile of the novel P₂T‐purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo 1995 ·British Journal of Pharmacology ·Robert G. Humphries, Wendy Tomlinson, J. A. Clegg, Anthony H. Ingall, Nicholas D. Kindon, P. Leff	39
19	Diastereoselectivity in the preparation of β-silyl esters from αβ-unsaturated esters and amides attached to chiral auxiliaries 1995 ·Journal of the Chemical Society Perkin Transactions 1 ·Ian Fleming, Nicholas D. Kindon	16
20	The stereochemistry of an SE2″ reaction of a chiral dienylmethylsilane 1987 ·Tetrahedron Letters ·Ian Fleming, Nicholas D. Kindon, Achintya Kumar Sarkar	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact